Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851985 | 0.83 | DGAT1 (0.37) | DGAT1PTGS2MAPT | |
| SCHEMBL27742436 | 0.79 | SMN1; SMN2 (0.38) | NPC1MAPT | |
| SCHEMBL20641167 | 0.78 | GRN (0.37) | KLKB1NPC1DGAT1F2RL1 | |
| SCHEMBL30785205 | 0.78 | KLKB1 (0.38) | KLKB1NPC1DGAT1F2RL1MAPT | |
| SCHEMBL17592980 | 0.77 | DGAT1 (0.38) | KLKB1NPC1DGAT1F2RL1 | |
| SCHEMBL2647079 | 0.76 | DGAT1 (0.31) | NPC1DGAT1PTGS2F2RL1 | |
| SCHEMBL23306274 | 0.75 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL19953625 | 0.75 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL24589275 | 0.75 | GRN (0.35) | KLKB1NPC1DGAT1 | |
| SCHEMBL2646509 | 0.75 | DGAT1 (0.30) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112399873-B | Triazole glycolate oxidase inhibitors | 坎特罗治疗有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-112399873-A | Triazole glycolate oxidase inhibitor | 奥凡生物科技公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2008135767-A1 | NEW TRIAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | KLKB1 2791/4885NPC1 2061/4885DGAT1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.